- Home
- SBLX vs GLMD Comparison
SBLX vs GLMD Comparison
Compare SBLX & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBLX | GLMD |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | Israel |
| Employees | 58 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | SBLX | GLMD |
|---|---|---|
| Price | $3.11 | $0.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.1M | 120.0K |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $0.41 |
| 52 Week High | $7.85 | $2.34 |
Technical Indicators
Market Signals| Indicator | SBLX | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 49.77 |
| Support Level | $2.83 | $0.52 |
| Resistance Level | $3.11 | $0.69 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 36.89 | 49.78 |
Price Performance
Historical ComparisonAbout SBLX StableX Technologies Inc.
StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.